Background Aiming at therapeutic targets has reduced the risk of organ failure in many
diseases such as diabetes or hypertension. Such targets have not been defined for …

Cases of active tuberculosis have been reported worldwide with the use of therapeutic
agents that inhibit tumour necrosis factor (TNF) α. TNFα has a central role in mycobacterial …

Objective: To evaluate the safety of biological treatments for rheumatoid arthritis (RA) using
results from randomised controlled trials (RCT). Methods: The literature was searched to …

Objective To determine the efficacy and safety of treatment with rituximab plus methotrexate
(MTX) in patients with active rheumatoid arthritis (RA) who had an inadequate response to …

Objective To evaluate the efficacy and safety of adalimumab (D2E7), a fully human
monoclonal tumor necrosis factor α antibody, in combination with methotrexate (MTX) in …

Background Etanercept, which blocks the action of tumor necrosis factor, reduces disease
activity in patients with long-standing rheumatoid arthritis. Its efficacy in reducing disease …

Background: In a phase II study, etanercept (recombinant human tumor necrosis factor
receptor [p75]: Fc fusion protein) safely produced rapid, dose-dependent improvement in …

Objective Tumor necrosis factor (TNF) is an important proinflammatory cytokine that
mediates inflammatory synovitis and articular matrix degradation in rheumatoid arthritis …

Objective To compare the clinical and radiographic outcomes in patients with rheumatoid
arthritis (RA) who received monotherapy with either etanercept or methotrexate (MTX) for 2 …

Background Baricitinib is an oral, reversible inhibitor of the Janus kinases JAK1 and JAK2
that may have therapeutic value in patients with rheumatoid arthritis. Methods We conducted …